Vertex Pharmaceuticals (NQ:VRTX)

517.49 -6.44 (-1.23%)

Delayed Quote Updated: 4:00 PM EDT, Oct 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2

...

20 21 22 23 24 25 26 27 28

...

78 79 Next >

Should You Buy Vertex Pharmaceuticals on the Dip Before Potentially Enormous News in January 2025? ↗

December 22, 2024

Via The Motley Fool

3 Fantastic Stocks That Could Enjoy a Santa Claus Rally ↗

December 21, 2024

Via The Motley Fool

My Top 10 Stocks to Buy for 2025 ↗

December 21, 2024

Via The Motley Fool

Vertex Wins An Early Approval; Why It Might Not Move Vertex's Beleaguered Stock ↗

December 20, 2024

The FDA signed off on Vertex's newest cystic fibrosis treatment. But it might not help beleaguered Vertex stock.

Via Investor's Business Daily

Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis

December 20, 2024

From Vertex Pharmaceuticals Incorporated

Via Business Wire

$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today ↗

December 13, 2024

Via Benzinga

The Ultimate Biotech Stock to Buy With $500 Right Now ↗

December 12, 2024

Via The Motley Fool

Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non-F508del TRIKAFTA-Responsive Variants

December 20, 2024

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Stock Market Tumbles, Treasury Yields Soar On Fed Rate Outlook: Weekly Review ↗

December 20, 2024

Micron, Vertex, Novo Nordisk and Nike were notable losers on news.

Via Investor's Business Daily

Topics Economy

Is Vertex Stock A Sell After Pain Drug Whiffs In Midstage Study? ↗

December 20, 2024

The company is still planning to move into Phase 3 testing, but analysts doubt the pain drug's future.

Via Investor's Business Daily

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

December 19, 2024

Via Benzinga

Why Is Vertex Pharmaceuticals Stock Trading Lower On Thursday After Back Pain Trial Data? ↗

December 19, 2024

Vertex Pharmaceuticals' suzetrigine reduced pain in Phase 2 trials for lumbosacral radiculopathy. Plans for Phase 3 trials follow regulatory discussions.

Via Benzinga

Vertex Plunges 10% After Its Non-Opioid Pain Drug Flops In Lower Back Pain ↗

December 19, 2024

The company says there was variability among placebo responses at various sites.

Via Investor's Business Daily

Vertex Non-Opioid Drug Doesn't Best Placebo In Back Pain Study. The Stock Is Plunging. ↗

December 19, 2024

Vertex Pharmaceuticals' drug reduced back pain significantly.

Via Investor's Business Daily

Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy

December 19, 2024

From Vertex Pharmaceuticals Incorporated

Via Business Wire

2 Unstoppable Stocks to Buy and Hold for the Next Decade ↗

December 19, 2024

Via The Motley Fool

2 Growth Stocks That Could Rocket Higher in 2025: Are They Right for Your Portfolio? ↗

December 17, 2024

Via The Motley Fool

Tesla To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Monday ↗

December 16, 2024

Via Benzinga

Prediction: These Could Be the Best-Performing Pharma and Biotech Stocks Through 2030 ↗

December 16, 2024

Via The Motley Fool

3 Unstoppable Stocks to Buy Right Now ↗

December 15, 2024

Via The Motley Fool

10 Health Care Stocks With Whale Alerts In Today's Session ↗

December 10, 2024

Via Benzinga

Vertex Has $5 Billion-Plus Opportunity In Pain And Kidney Disease Programs, Analyst Upgrades Stock ↗

December 09, 2024

Jefferies upgrades Vertex Pharmaceuticals to Buy, highlighting a promising pipeline and $5 billion-$7 billion growth potential from pain and kidney treatments.

Via Benzinga

A Glimpse Into The Expert Outlook On Vertex Pharmaceuticals Through 19 Analysts ↗

December 09, 2024

Via Benzinga

2 No-Brainer Stocks to Buy Before the End of 2024 ↗

December 09, 2024

Via The Motley Fool

Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the American Society of Hematology (ASH) Annual Meeting and Exposition and Provides Program Update

December 08, 2024

From Vertex Pharmaceuticals Incorporated

Via Business Wire

3 No-Brainer Growth Stocks to Buy in December ↗

December 07, 2024

Via The Motley Fool

Should You Forget Pfizer and Buy These Unstoppable Stocks Instead? ↗

December 05, 2024

Via The Motley Fool

FDA-Approved Sickle Cell Therapies From Bluebird Bio And Vertex Join Medicaid Innovation Program ↗

December 04, 2024

CMS launches an outcomes-based model to expand access to FDA-approved gene therapies for sickle cell disease, aiming to improve health outcomes and lower costs.

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

December 04, 2024

Via Benzinga

It’s Been A Tough Month For Healthcare Stocks ↗

December 02, 2024

It’s been a very difficult month for the healthcare sector not only because of disappointing company news but also disruption caused by the election and future policy issues.

Via Talk Markets

Topics ETFs Stocks / Equities

< Previous 1 2

...

20 21 22 23 24 25 26 27 28

...

78 79 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.